MEDICAL stock levels “remain stable”, the Health Department has said following concerns raised by the head of the NHS about supply pressures stemming from the conflict in the Middle East.
Head of operational resilience James Basilio-Mason stated that officials were continuing to monitor global supply chain developments “to ensure ongoing resilience”.
His comments come after NHS chief executive Jim Mackey highlighted fears that the war in Iran could disrupt the supply of medicines and equipment and drive up costs for the service.
As the instability in the region has grown, so has uncertainty surrounding movements through critical trade corridors and the wider impact of rising prices for key materials and essential goods.
Following questions from the JEP about Jersey’s position in relation to medicine stocks, Mr Basilio-Mason said: “We are aware of the concerns raised regarding NHS medical supply pressures linked to the Middle East conflict.”
He continued: “We hold reserves of essential medicines and supplies, and we are not currently experiencing shortages or concerns.
“Our stock levels remain stable, and we continue to monitor global supply chain developments to ensure ongoing resilience.”
Mr Basilio-Mason also noted that: “Through our close relationship with the NHS Supply Chain, we are linked into the National Supply Disruption Response (NSDR), which provides co-ordinated support and mitigation should any supply issues arise.”
